HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A cyclopalladated complex interacts with mitochondrial membrane thiol-groups and induces the apoptotic intrinsic pathway in murine and cisplatin-resistant human tumor cells.

AbstractBACKGROUND:
Systemic therapy for cancer metastatic lesions is difficult and generally renders a poor clinical response. Structural analogs of cisplatin, the most widely used synthetic metal complexes, show toxic side-effects and tumor cell resistance. Recently, palladium complexes with increased stability are being investigated to circumvent these limitations, and a biphosphinic cyclopalladated complex {Pd(2) [S((-))C(2), N-dmpa](2) (μ-dppe)Cl(2)} named C7a efficiently controls the subcutaneous development of B16F10-Nex2 murine melanoma in syngeneic mice. Presently, we investigated the melanoma cell killing mechanism induced by C7a, and extended preclinical studies.
METHODS:
B16F10-Nex2 cells were treated in vitro with C7a in the presence/absence of DTT, and several parameters related to apoptosis induction were evaluated. Preclinical studies were performed, and mice were endovenously inoculated with B16F10-Nex2 cells, intraperitoneally treated with C7a, and lung metastatic nodules were counted. The cytotoxic effects and the respiratory metabolism were also determined in human tumor cell lines treated in vitro with C7a.
RESULTS:
Cyclopalladated complex interacts with thiol groups on the mitochondrial membrane proteins, causes dissipation of the mitochondrial membrane potential, and induces Bax translocation from the cytosol to mitochondria, colocalizing with a mitochondrial tracker. C7a also induced an increase in cytosolic calcium concentration, mainly from intracellular compartments, and a significant decrease in the ATP levels. Activation of effector caspases, chromatin condensation and DNA degradation, suggested that C7a activates the apoptotic intrinsic pathway in murine melanoma cells. In the preclinical studies, the C7a complex protected against murine metastatic melanoma and induced death in several human tumor cell lineages in vitro, including cisplatin-resistant ones. The mitochondria-dependent cell death was also induced by C7a in human tumor cells.
CONCLUSIONS:
The cyclopalladated C7a complex is an effective chemotherapeutic anticancer compound against primary and metastatic murine and human tumors, including cisplatin-resistant cells, inducing apoptotic cell death via the intrinsic pathway.
AuthorsFabiana A Serrano, Alisson L Matsuo, Priscila T Monteforte, Alexandre Bechara, Soraya S Smaili, Débora P Santana, Tiago Rodrigues, Felipe V Pereira, Luis S Silva, Joel Machado Jr, Edson L Santos, João B Pesquero, Rafael M Martins, Luiz R Travassos, Antonio C F Caires, Elaine G Rodrigues
JournalBMC cancer (BMC Cancer) Vol. 11 Pg. 296 (Jul 14 2011) ISSN: 1471-2407 [Electronic] England
PMID21756336 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Mitochondrial Proteins
  • Organometallic Compounds
  • Sulfhydryl Compounds
  • bcl-2-Associated X Protein
  • Palladium
  • Caspases
  • Cisplatin
Topics
  • Animals
  • Antineoplastic Agents (chemistry, metabolism, pharmacology)
  • Apoptosis (drug effects)
  • Caspases (metabolism)
  • Cell Line, Tumor
  • Cisplatin (pharmacology)
  • Drug Resistance, Neoplasm
  • Enzyme Activation (drug effects)
  • Humans
  • Lung Neoplasms (metabolism, prevention & control, secondary)
  • Male
  • Melanoma, Experimental (drug therapy, metabolism, pathology)
  • Membrane Potential, Mitochondrial (drug effects)
  • Mice
  • Mice, Inbred C57BL
  • Mitochondria, Liver (drug effects, metabolism, physiology)
  • Mitochondrial Membranes (metabolism)
  • Mitochondrial Proteins (drug effects, metabolism)
  • Molecular Structure
  • Organometallic Compounds (chemistry, metabolism, pharmacology)
  • Palladium (chemistry, metabolism, pharmacology)
  • Rats
  • Rats, Wistar
  • Sulfhydryl Compounds (metabolism)
  • bcl-2-Associated X Protein (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: